RE: Is the week or even month for an RNS????6 Mar 2023 11:31
Morning all
Completely get investors frustrations over the yrs in Hemo , & currently awaiting update ,
However had some cracking RNS in 2023 & current position looks a whole lot rosier than a yr ago .
Let’s hope the next update is a whacker for all invested .
Current & recent positive position -
Hemos Horizon has plenty of positive action to look forward to for all invested for 2023
Vlad certainly been cranking up the subliminal tweets in recent weeks from Music to science ‘ a jovial yet very positive gaffer & why not the Great work Hemo are doing .
.Extra cash in the bank & placement successful
.Reason for additional funds as stated in the RNS , as had millions in the bank prior to placement was to accelerate to clinical trials .
Imo
Vlad & the company saw an opportunity for rapid growth that simply required additional financing, to fulfil an initial goal then the eventual extra profits realized from the company's clinical trials that may push its stock price substantially higher. # Stock re rate
Further News could land any day & without stock you will likely have to pay a premium imo
.Current position looks very positive for stockholders
In brief -
.Weekly hinting tweets from the Vlad - subliminal meaning within , certainly active of late .
.New scientific premises last year - we’ve all seen the pics
. Investors being fed regular detailed RNS on the current science position & forward plan .( plenty of companies out there at present with a conveyor belt of poor news or silence & Hemo has the benefit of being somewhat insulated from the current war & market volatility )
.Cash in the bank prior to raise & with the raise accelerates Clinical trials as stated in the RNs
Vlad stated
‘ I am pleased to announce this placing, which will enable the Company to progress with these two key product candidates’.
.Superb science - on multiple mind boggling potential fronts - CBR , CAR-T
In Brief
CBR allows the development of:
(1) off-the-shelf cell therapies against infectious disease.
(2) biopharmaceuticals to eliminate any potential virus in the course of infection or to be used as a preventive treatment.
CAR-T
‘ The IND is needed to obtain authorization from the FDA to commence Phase I clinical trials of HEMO-CAR-T. Following completion of all tests across all PQ runs, data will be compiled for inclusion in the IND submission pack. ‘
& Clinical trials next on the horizon - which is the big stock mover as noted by Vlad previously & I agree
Transformational year for Hemo imo , been here years & great to see the science tree at last bearing fruit for investors.
Good luck to all invested & Fetch the IND Grog